MARKET

ERAS

ERAS

Erasca, Inc.
NASDAQ
19.50
+1.60
+8.94%
Pre Market: 19.50 0 0.00% 04:21 07/15 EDT
OPEN
18.48
PREV CLOSE
17.90
HIGH
19.74
LOW
18.20
VOLUME
1.60K
TURNOVER
0
52 WEEK HIGH
24.28
52 WEEK LOW
1.330
MARKET CAP
6.06B
P/E (TTM)
-20.9048
1D
5D
1M
3M
1Y
5Y
1D
Is Erasca (ERAS) Stock Trading At A Premium After New Trial Data?
Simply Wall St · 2h ago
Erasca Announces Major Equity Offering to Fund Oncology
TipRanks · 3h ago
ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS
PR Newswire · 9h ago
Analysts Offer Insights on Healthcare Companies: Erasca (ERAS) and Tenet Healthcare (THC)
TipRanks · 14h ago
Erasca price target raised to $24 from $21 at Jefferies
TipRanks · 14h ago
Erasca Unveils Updated Cancer Candidate Progress, Maps Path Toward Pivotal Cancer Trials
Benzinga · 16h ago
Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire · 18h ago
BUZZ-U.S. STOCKS ON THE MOVE-Bank of America, Analog Devices, Newmont
Reuters · 18h ago
More
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Webull offers Erasca Inc stock information, including NASDAQ: ERAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERAS stock methods without spending real money on the virtual paper trading platform.